P163 Association between biomarkers and therapeutic pathway in patients with SLE
Sign Up to like & getrecommendations! Published in 2021 at "Rheumatology"
DOI: 10.1093/rheumatology/keab247.159
Abstract: Background/Aims SLE is heterogeneous in clinical presentation, underlying immunology, and response to therapy. Patients with severe or resistant disease receive cyclophosphamide or rituximab. Although effective, late use of these therapies entails cumulative damage. Emerging predictors… read more here.
Keywords: ifn score; none; includednot; association ... See more keywords